CA1337265C - Anticorps administres par voie orale pour le traitement de patients immunodeprimes et composition utilisee a cet effet - Google Patents

Anticorps administres par voie orale pour le traitement de patients immunodeprimes et composition utilisee a cet effet

Info

Publication number: CA1337265C
Authority: CA; Canada
Prior art keywords: composition; milk; enteric; immunogens; hiv
Prior art date: 1988-08-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 607656

Other languages

English (en)

Inventor

Thomas Julius Borody

David A. Cooper

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Numico Research Australia Pty Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-04

Filing date

1989-08-04

Publication date

1995-10-10

1989-08-04 Application filed by Individual filed Critical Individual

1995-10-10 Application granted granted Critical

1995-10-10 Publication of CA1337265C publication Critical patent/CA1337265C/fr

2012-10-10 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 23
230000028993 immune response Effects 0.000 title claims abstract description 14
238000009175 antibody therapy Methods 0.000 title description 2
235000013336 milk Nutrition 0.000 claims abstract description 32
210000004080 milk Anatomy 0.000 claims abstract description 32
239000008267 milk Substances 0.000 claims abstract description 32
206010022678 Intestinal infections Diseases 0.000 claims abstract description 21
241001465754 Metazoa Species 0.000 claims abstract description 20
206010061217 Infestation Diseases 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 12
208000030507 AIDS Diseases 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
238000011321 prophylaxis Methods 0.000 claims abstract description 6
241000725303 Human immunodeficiency virus Species 0.000 claims description 27
208000015181 infectious disease Diseases 0.000 claims description 17
230000000890 antigenic effect Effects 0.000 claims description 11
230000002163 immunogen Effects 0.000 claims description 7
241000223935 Cryptosporidium Species 0.000 claims description 6
241000700605 Viruses Species 0.000 claims description 6
241000283707 Capra Species 0.000 claims description 5
244000005700 microbiome Species 0.000 claims description 5
241000132028 Bellis Species 0.000 claims description 4
241000589877 Campylobacter coli Species 0.000 claims description 4
241000589875 Campylobacter jejuni Species 0.000 claims description 4
241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
241000193163 Clostridioides difficile Species 0.000 claims description 4
241000224432 Entamoeba histolytica Species 0.000 claims description 4
241000607142 Salmonella Species 0.000 claims description 4
241000223997 Toxoplasma gondii Species 0.000 claims description 4
241000607447 Yersinia enterocolitica Species 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
229940007078 entamoeba histolytica Drugs 0.000 claims description 4
244000000021 enteric pathogen Species 0.000 claims description 4
241001529453 unidentified herpesvirus Species 0.000 claims description 4
229940098232 yersinia enterocolitica Drugs 0.000 claims description 4
241000607534 Aeromonas Species 0.000 claims description 3
241000726107 Blastocystis hominis Species 0.000 claims description 3
241000701022 Cytomegalovirus Species 0.000 claims description 3
241000588724 Escherichia coli Species 0.000 claims description 3
241000224466 Giardia Species 0.000 claims description 3
241000545499 Mycobacterium avium-intracellulare Species 0.000 claims description 3
241000702670 Rotavirus Species 0.000 claims description 3
229940011597 blastocystis hominis Drugs 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
235000008476 powdered milk Nutrition 0.000 claims 3
238000009109 curative therapy Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 10
230000001010 compromised effect Effects 0.000 abstract 1
206010012735 Diarrhoea Diseases 0.000 description 7
241000283690 Bos taurus Species 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
206010069691 HIV enteropathy Diseases 0.000 description 5
210000003022 colostrum Anatomy 0.000 description 5
235000021277 colostrum Nutrition 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
206010025476 Malabsorption Diseases 0.000 description 4
208000004155 Malabsorption Syndromes Diseases 0.000 description 4
108010074605 gamma-Globulins Proteins 0.000 description 4
244000052769 pathogen Species 0.000 description 4
239000000843 powder Substances 0.000 description 4
208000016261 weight loss Diseases 0.000 description 4
230000004580 weight loss Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
208000003322 Coinfection Diseases 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
235000015243 ice cream Nutrition 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
208000012124 AIDS-related disease Diseases 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000820057 Ithone Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004187 Spiramycin Substances 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
244000000074 intestinal pathogen Species 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
235000020166 milkshake Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229960001294 spiramycin Drugs 0.000 description 1
229930191512 spiramycin Natural products 0.000 description 1
235000019372 spiramycin Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
235000008939 whole milk Nutrition 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA 607656 1988-08-04 1989-08-04 Anticorps administres par voie orale pour le traitement de patients immunodeprimes et composition utilisee a cet effet Expired - Fee Related CA1337265C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPI967488		1988-08-04
AUPI9674		1988-08-04

Publications (1)

Publication Number	Publication Date
CA1337265C true CA1337265C (fr)	1995-10-10

Family

ID=3773261

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 607656 Expired - Fee Related CA1337265C (fr)	1988-08-04	1989-08-04	Anticorps administres par voie orale pour le traitement de patients immunodeprimes et composition utilisee a cet effet

Country Status (1)

Country	Link
CA (1)	CA1337265C (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9433651B2 (en)	2013-06-05	2016-09-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9463208B2 (en)	2010-02-01	2016-10-11	Rebiotix, Inc.	Bacteriotherapy for clostridium difficile colitis
US9511100B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en)	2013-06-05	2017-07-04	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en)	2013-06-05	2017-10-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10226431B2 (en)	2015-06-09	2019-03-12	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10383901B2 (en)	2013-06-05	2019-08-20	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10799539B2 (en)	2015-06-09	2020-10-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en)	2015-06-09	2021-02-02	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture

1989
- 1989-08-04 CA CA 607656 patent/CA1337265C/fr not_active Expired - Fee Related

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11986500B2 (en)	2010-02-01	2024-05-21	Rebiotix Inc	Bacteriotherapy for clostridium difficile colitis
US9463208B2 (en)	2010-02-01	2016-10-11	Rebiotix, Inc.	Bacteriotherapy for clostridium difficile colitis
US12303537B2 (en)	2010-02-01	2025-05-20	Ferring Microbiome Inc.	Bacteriotherapy for clostridium difficile colitis
US12102655B2 (en)	2010-02-01	2024-10-01	Rebiotix Inc.	Bacteriotherapy for clostridium difficile colitis
US9629881B2 (en)	2010-02-01	2017-04-25	Rebiotix, Inc.	Bacteriotherapy for clostridium difficile colitis
US10471107B2 (en)	2013-06-05	2019-11-12	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10434125B2 (en)	2013-06-05	2019-10-08	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en)	2013-06-05	2017-07-04	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en)	2013-06-05	2017-10-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en)	2013-06-05	2019-08-20	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10391129B2 (en)	2013-06-05	2019-08-27	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9675648B2 (en)	2013-06-05	2017-06-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10434126B2 (en)	2013-06-05	2019-10-08	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US11554143B2 (en)	2013-06-05	2023-01-17	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10434124B2 (en)	2013-06-05	2019-10-08	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9433651B2 (en)	2013-06-05	2016-09-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10493111B2 (en)	2013-06-05	2019-12-03	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10603341B2 (en)	2013-06-05	2020-03-31	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10610547B2 (en)	2013-06-05	2020-04-07	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10624932B2 (en)	2013-06-05	2020-04-21	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10688137B2 (en)	2013-06-05	2020-06-23	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9642880B2 (en)	2013-06-05	2017-05-09	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10391064B2 (en)	2015-06-09	2019-08-27	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en)	2015-06-09	2021-02-02	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US11642381B2 (en)	2015-06-09	2023-05-09	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US11654164B2 (en)	2015-06-09	2023-05-23	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US12036250B2 (en)	2015-06-09	2024-07-16	Rebiotix Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en)	2015-06-09	2020-10-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10226431B2 (en)	2015-06-09	2019-03-12	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture

Legal Events

Date	Code	Title	Description
2007-10-10	MKLA	Lapsed

Publication	Publication Date	Title
Korhonen et al.	2000	Bovine milk antibodies for health
EP0918528B1 (fr)	2003-05-21	Utilisation de lait et/ou d'oeufs hyperimmunises pour traiter les lesions gastro-intestinales
US5260057A (en)	1993-11-09	Method and product for the treatment of gastric disease
Ebina	1996	Prophylaxis of rotavirus gastroenteritis using immunoglobulin
EP0990001B1 (fr)	2006-05-10	Procedes de production d'immunoglobuline a dans du lait
CH627079A5 (en)	1981-12-31	Process for preparing a protein concentrate containing immunological factors of milk origin
US5753228A (en)	1998-05-19	Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies
NZ335170A (en)	2001-08-31	Oral administration of chicken yolk Ig-gamma antibodies to treat disease
WO1997020577A1 (fr)	1997-06-12	Formulation therapeutique amelioree et procede correspondant
EP0391416A1 (fr)	1990-10-10	Procédé de préparation d'un agent thérapeutique pour le traitement d'infections par rotavirus
EP0706400A1 (fr)	1996-04-17	Formulation et methode therapeutiques
CA1337265C (fr)	1995-10-10	Anticorps administres par voie orale pour le traitement de patients immunodeprimes et composition utilisee a cet effet
Tawfeek et al.	2003	Efficacy of an infant formula containing anti-Escherichia coli colostral antibodies from hyperimmunized cows in preventing diarrhea in infants and children: a field trial
US4971794A (en)	1990-11-20	Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
EP0102831B1 (fr)	1989-05-31	Production d'anticorps
Feeney et al.	2018	The role of immunoglobulins from bovine colostrum and milk in human health promotion
JPH11512746A (ja)	1999-11-02	乳漿中の免疫グロブリンの単離方法
WO1999002188A1 (fr)	1999-01-21	Anticorps de jaune d'oeuf de poule, diriges contre les antigenes de clostridium difficile et leur utilisation dans le traitement de la colite pseudomembraneuse
US20100303830A1 (en)	2010-12-02	PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK
JPH04275232A (ja)	1992-09-30	胃炎，胃または十二指腸潰瘍予防食品
IE76730B1 (en)	1997-11-05	Method and product for the treatment of gastric disease
EP1044690B1 (fr)	2005-08-03	Utilisation et procédé de préparation de mélanges de protéines plasmatiques d'origine animale riches en gamma-globulines
WO1992002538A1 (fr)	1992-02-20	Produit et procede de transfert de constituants de prevention de maladies derives du colostrum a travers les voies gastro-intestinales
JP2001502309A (ja)	2001-02-20	溶血性尿毒性症候群を予防するための経口投与薬剤を製造するために免疫グロブリン製剤を使用する方法
WO1998055143A1 (fr)	1998-12-10	Formulation orale a teneur en lipides reduite contenant une proteine therapeutique derivee du jaune d'oeuf